Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.
Seventy percent of liver cancer patients had either a partial response or stable disease.
More treatment options may soon become available for those with hepatocellular carcinoma, which is often diagnosed late.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.